文献速递病毒性肝炎

REAL-B评分:口服抗病毒治疗慢性乙肝患者肝癌风险预测

Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy.
PubMed 文献 · J Infect Dis · 2020-01-01

研究基于美国及亚太25个中心的8048例接受口服抗病毒治疗的亚洲慢性乙肝患者,按2:1随机分为推导组与验证组,建立含7个变量的REAL-B肝癌风险评分。评分分低、中、高三档,3、5、10年肝癌风险的AUC均>0.80,显著优于其他风险模型(p<.001)。

要点

  • REAL-B评分含7个常规临床变量,分0-3、4-7、8-13三档风险。
  • 3、5、10年肝癌风险AUC均>0.80,显著优于其他模型(p<.001)。
  • 评分可用于指导接受口服抗病毒治疗患者的肝癌监测策略。

核心结论

  • REAL-B评分可为接受口服抗病毒治疗的亚洲慢性乙肝患者提供3个明确的肝癌风险分层,用于指导肝癌监测策略。

研究设计与样本

  • 多中心队列研究,从美国及亚太地区25个中心招募接受口服抗病毒治疗的成年亚洲慢性乙肝患者。
  • 排除合并丙肝、丁肝或HIV感染、入组前或入组1年内发生肝癌、随访不足1年的患者。
  • 按2:1比例随机分为推导组(n=5365)和验证组(n=2683),共8048例。

主要发现

  • REAL-B模型纳入7个变量:男性、年龄、饮酒、糖尿病、基线肝硬化、血小板计数和甲胎蛋白。
  • 评分分级为0-3低风险、4-7中风险、8-13高风险。
  • 3、5、10年肝癌风险的AUC均>0.80,且显著高于其他风险模型(p<.001)。

关键数值与推荐

  • REAL-B评分风险分级:0-3低风险,4-7中风险,8-13高风险。
  • 3、5、10年肝癌风险AUC均>0.80,显著优于其他风险模型(p<.001)。

临床怎么用

  • 对接受口服抗病毒治疗的亚洲慢性乙肝患者可用REAL-B评分进行肝癌风险分层,据此制定监测策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients on oral antiviral (OAV) therapy remain at hepatocellular carcinoma (HCC) risk. Risk prediction tools distinguishing treated patients with residual HCC risk are limited. The aim of this study was to develop an accurate, precise, simple-to-use HCC risk score using routine clinical variables among a treated Asian cohort. METHODS: Adult Asian chronic hepatitis B (CHB) patients on OAV were recruited from 25 centers in the United States and the Asia-Pacific region. Excluded persons were coinfected with hepatitis C, D, or human immunodeficiency virus, had HCC before or within 1 year of study entry, or their follow-up was <1 year. Patients were randomized to derivation and validation cohorts on a 2:1 ratio. Statistically significant predictors from multivariate modeling formed the Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for HBV (REAL-B) score. RESULTS: A total of 8048 patients were randomized to the derivation (n = 5365) or validation group (n = 2683). The REAL-B model included 7 variables (male gender, age, alcohol use, diabetes, baseline cirrhosis, platelet count, and alpha fetoprotein), and scores were categorized as follows: 0-3 low risk, 4-7 moderate risk, and 8-13 high risk. Area under receiver operating characteristics were >0.80 for HCC risk at 3, 5, and 10 years, and these were significantly higher than other risk models (p < .001). CONCLUSIONS: The REAL-B score provides 3 distinct risk categories for HCC development in Asian CHB patients on OAV guiding HCC surveillance strategy.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Yang HI, Yeh ML, Wong GL, et al. Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. J Infect Dis. 2020. PMID: 31550363. doi:10.1093/infdis/jiz477

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。